Antiproteinuric therapy and fabry nephropathy: Sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-β

Journal of the American Society of Nephrology

Volumn 18, Issue 9, 2007, Pages 2609-2617

  Tahir, Hindia ^a   Jackson, Leslie L ^a   Warnock, David G ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AGALSIDASE ALFA; AGALSIDASE BETA; ALBUMIN; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; ATORVASTATIN; CLOPIDOGREL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EZETIMIBE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; ISOSORBIDE; LEVOTHYROXINE; LISINOPRIL; LOSARTAN; METOPROLOL; PLACEBO; ROSUVASTATIN; VALPROIC ACID; WARFARIN;

ACUTE CHOLECYSTITIS; ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHOLECYSTECTOMY; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE URINE LEVEL; DIALYSIS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; SEIZURE; THROMBOEMBOLISM; TREATMENT OUTCOME; URINARY EXCRETION;

EID: 34548474768     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006121400     Document Type: Article

References (30)

1. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin HA 3rd, Kopp JB: Natural history of Fabry renal disease: Influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81: 122-138, 2002
2. Desnick R, Ioannou Y, Eng C: Alpha-galactosidase A deficiency: Fabry disease. In: The Metabolic Bases of Inherited Disease, 8th Ed., edited by Scriver C, Beaudet A, Sly W, Valle D, New York, McGraw-Hill, 2001, pp 3733-3774
3. MacDermot KD, Holmes A, Miners AH: Natural history of Fabry disease in affected males and obligate carrier females. J Inherit Metab Dis 24[Suppl 2]: 13-14, discussion 11-12, 2001
4. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ: Safety and efficacy of recombinant human alpha-galactosidase A: Replacement therapy in Fabry's disease. N Engl J Med 345: 9-16, 2001
5. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP: Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75: 65-74, 2004
6. Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R: Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int 13: 223-235, 1978
7. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO: Long-term therapy with agalsidase alfa for Fabry disease: Safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21: 345-354, 2006
8. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ: Agalsidase-beta therapy for advanced Fabry disease: A randomized trial. Ann Intern Med 146: 77-86, 2007
9. Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C: Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69: 1216-1221, 2006
10. Germain D, Waldek S, Banikazemi M, Bushinsky D, Charrow J, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N: Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18: 1547-1557, 2007
11. Warnock DG: Fabry disease: Diagnosis and management, with emphasis on the renal manifestations. Curr Opin Nephrol Hypertens 14: 87-95, 2005
12. Schiffmann R, Askari H, Timmons M, Robinson C, Benko W, Brady R, Ries M: Weekly enzyme replacement therapy may slow decline of renal function in Fabry patients who are on long-term biweekly dosing. J Am Soc Nephrol 18: 1576-1583, 2007
13. Warnock DG: Enzyme replacement therapy and Fabry kidney disease: Quo Vadis? J Am Soc Nephrol 18: 1368-1370, 2007
14. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43: S1-S290, 2004
15. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49: S12-S154, 2007
16. De Groot WP: Angiokeratoma corporis diffusum Fabry. Dermatologica 136: 432-433, 1968
17. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123: 754-762, 1995
18. Schieppati A, Remuzzi G: Proteinuria and its consequences in renal disease. Acta Paediatr Suppl 92: 9-13, discussion 15, 2003
19. Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR: Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8: 539-548, 2006
20. Hebert LA, Kusek JW, Greene T, Agodoa LY, Jones CA, Levey AS, Breyer JA, Faubert P, Rolin HA, Wang SR: Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. Hypertension 30: 428-435, 1997
21. Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM: Effects of blood pressure level on progression of diabetic nephropathy: Results from the RENAAL study. Arch Intern Med 163: 1555-1565, 2003
22. Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL study. Kidney Int 63: 1499-1507, 2003
23. Ruggenenti P, Perna A, Remuzzi G: Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int 63: 2254-2261, 2003
24. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL: The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: Results of the African American Study of Kidney Disease and Hypertension. Arch Intern Med 165: 947-953, 2005
25. Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J Jr, Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ: Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitations. J Am Soc Nephrol 16: 3027-3037, 2005
26. Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D: Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial. J Am Soc Nephrol 18: 1540-1546, 2007
27. Warnock DG: The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study (NCT00446862). Available at: http://www.clinicaltrials.gov/ct/ show/NCT00446862;jsessionid=126C99ABC0ABB339746B9522A408C82C?order=12. Acccessed July 17, 2007
28. Ojo A, Meier-Kriesche HU, Friedman G, Hanson J, Cibrik D, Leichtman A, Kaplan B: Excellent outcome of renal transplantation in patients with Fabry's disease. Transplantation 69: 2337-2339, 2000
29. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39: S1-S266, 2002
30. Stevens LA, Coresh J, Greene T, Levey AS: Assessing kidney function: Measured and estimated glomerular filtration rate. N Engl J Med 354: 2473-2483, 2006